Trials / Completed
CompletedNCT01246960
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ramucirumab | Administered intravenously |
| DRUG | Placebo | Administered intravenously |
| DRUG | Oxaliplatin | Administered intravenously |
| DRUG | Leucovorin | Administered intravenously |
| DRUG | 5-Fluorouracil | Administered intravenously |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2013-09-01
- Completion
- 2014-05-01
- First posted
- 2010-11-24
- Last updated
- 2014-10-08
- Results posted
- 2014-10-08
Locations
58 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01246960. Inclusion in this directory is not an endorsement.